国泰海通证券股份有限公司 关于上海宣泰医药科技股份有限公司 上海证券交易所： 国泰海通证券股份有限公司（以下简称"国泰海通"、"保荐人"）作为上海 宣泰医药科技股份有限公司（以下简称"宣泰医药"或"公司"）首次公开发行 股票并在科创板上市的保荐人，根据《中华人民共和国公司法》《中华人民共和 国证券法》 《证券发行上市保荐业务管理办法》 《上海证券交易所科创板股票上市 规则》 （以下简称"《上市规则》" ）和《上海证券交易所上市公司自律监管指引第 持续督导期间"）的规范运作情况进行了现场检查，现就现场检查的有关情况报 告如下： 一、本次现场检查的基本情况 （一）保荐人 国泰海通证券股份有限公司 沈玉峰、程万里、程恺 （五）现场检查内容 现场检查人员对本持续督导期内发行人公司治理及内部控制、信息披露、独 立性、与关联方的资金往来、募集资金使用情况、关联交易、对外担保、重大对 外投资、公司经营状况以及承诺履行情况等方面进行了现场检查。 （六）现场检查手段 查看上市公司主要生产经营场所并与上市公司董事、监事、高级管理人员及 有关人员访谈；查阅公司本持续督导期间召开的历次三会会议资料；查阅公司建 立或更新的有关内控制度 ...

Core Viewpoint - The report outlines the financial performance and operational status of Shanghai Zhijiang Biotechnology Co., Ltd. for the year 2024, highlighting a net profit loss and ongoing strategic adjustments in response to market changes [2][8]. Financial Performance - The net profit attributable to shareholders, excluding non-recurring gains and losses, was -128.27 million yuan, indicating a reduction in losses by 26.96 million yuan compared to the previous year [2][15]. - Revenue for 2024 was 178.65 million yuan, a decrease of 34.88% from 274.33 million yuan in 2023 [15]. - The company reported a basic earnings per share of -0.67 yuan, consistent with the diluted earnings per share [15]. Operational Adjustments - The company has accelerated its operational strategy adjustments due to a decline in revenue and market demand, while production and operations remain normal without significant risks [2][8]. - The company has established internal systems and decision-making processes to comply with legal regulations and ensure proper information disclosure [3][8]. Risk Management - The report identifies several risks, including significant financial losses, core technology leakage, and intensified market competition, which could adversely affect the company's operations and financial status [9][10][11]. - The company has not encountered any major violations or undisclosed risks during the reporting period [4][5]. Research and Development - R&D expenditure for 2024 was 58.78 million yuan, accounting for 32.90% of total revenue, reflecting a focus on innovation despite a slight decrease in R&D spending compared to the previous year [16][19]. - The company has developed over 500 products and holds numerous patents, indicating a strong commitment to maintaining a competitive edge in the molecular diagnostics industry [19][20]. Market Position - The company has established a solid reputation in the molecular diagnostics field, with products widely used in major hospitals and medical institutions across China and internationally [20][21]. - The company has received recognition for its rapid response to public health emergencies, enhancing its brand image and market presence [21][22].

国泰海通证券研报表示，面向未来，仍然保持乐观，中国A/H指数有望进一步缓步推高：1)遍历冲击 后，投资人对经济形势的认识已然充分。2)中国股市的无风险利率下降，海外预期降低、固收预期降 低，股市是解决社会资本开支下降与资产管理需求上升的关键破局点。3)围绕投资者为本、投融资相协 调的资本市场改革拉开序幕并提速，中国市场的底色向"可投资、重回报"转变，股市风险溢价降低。因 此，贴现率下降是如今中国股市上升的重要动力。 ...

Core Viewpoint - The report summarizes the sponsorship and underwriting process for the initial public offering (IPO) of Liaoning Dingjide Petrochemical Co., Ltd, detailing the issuance of 33.36667 million shares at a price of RMB 21.88 per share, raising a total of RMB 730.0627 million, with a net amount of RMB 656.9027 million after deducting issuance costs [1][2][3]. Group 1: Sponsorship and Issuance Details - The IPO was approved by the China Securities Regulatory Commission (CSRC) and listed on the Shanghai Stock Exchange on August 18, 2022 [1][2]. - The registered capital of Liaoning Dingjide Petrochemical Co., Ltd is RMB 134.511667 million, with a legal representative named Wu Chunye [2][3]. - The company’s actual controller is Zhang Zaiming, and the securities code is 603255 [2]. Group 2: Sponsorship Responsibilities - During the due diligence phase, the sponsoring institution coordinated with various intermediaries, conducted thorough investigations, and prepared necessary documentation for the IPO [3][4]. - In the ongoing supervision phase, the sponsor focused on preventing resource misappropriation by major shareholders and ensuring compliance with corporate governance standards [3][4]. Group 3: Major Events and Issues - A change in the designated sponsor representative occurred in February 2023, with Zhang Yuheng replacing Ding Shangjie due to a job change [4][5]. - The company faced issues related to non-operating fund occupation by related parties in 2024, which were not promptly reported to the sponsor [5][6]. - The sponsor conducted a special inspection regarding fund occupation and provided training to the company's management to enhance internal control [5][6]. Group 4: Fund Usage and Compliance - The sponsor reviewed the usage of raised funds, confirming compliance with CSRC and stock exchange regulations, with all funds being used appropriately [6]. - The report indicates that the company has completed the use of all funds raised from the IPO as of the report date [6].

Core Viewpoint - Jilin Zhongyan High Polymer Materials Co., Ltd. has successfully completed its initial public offering (IPO) and is under continuous supervision by Guotai Junan Securities Co., Ltd. from September 20, 2023, to December 31, 2026, ensuring compliance with regulatory requirements and effective corporate governance [3][4]. Group 1: Company Overview - The company has issued shares with a par value of RMB 1 each, raising a net amount of RMB 799.71 million [3]. - The company operates in the PEEK (Polyether Ether Ketone) materials sector, which is characterized by high technical barriers and limited competition in large-scale industrial production [9][17]. Group 2: Financial Performance - For the year 2024, the company reported a revenue of RMB 277.09 million, a decrease of 5.05% compared to RMB 291.84 million in 2023 [16]. - The gross profit margin for the company was 40.08%, slightly up from 39.48% in the previous year, indicating stable profitability despite revenue decline [10][16]. - The net assets attributable to shareholders increased to RMB 135.45 million, reflecting an 8.80% growth from RMB 124.50 million in 2023 [16]. Group 3: Risk Factors - The company faces core competitiveness risks due to the reliance on key technical personnel, whose departure could adversely affect operations [10]. - Operational risks are present as the company expands its business scale, necessitating enhanced management capabilities to adapt to changing environments [10]. - Financial risks include potential declines in gross margin due to increased competition and rising raw material costs, which could impact profitability [11][16]. Group 4: Research and Development - The company has significantly increased its R&D investment, with total R&D expenditures reaching RMB 3.19 million in 2024, accounting for 11.52% of revenue, up from 7.91% in 2023 [23]. - The company has developed new medical-grade PEEK products and completed various biocompatibility evaluations, transitioning from research to development phases [24]. Group 5: Market Position - The company is recognized as a national high-tech enterprise and has established itself as a leader in the domestic PEEK market, surpassing international competitors in sales volume [17][22]. - The company has a diverse product range, including 89 specifications of PEEK products, which enhances its market resilience and competitive advantage [19].

国泰海通证券股份有限公司 关于峰岹科技（深圳）股份有限公司 差异化分红事项的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 峰岹科技（深圳）股份有限公司（以下简称"峰岹科技"或"公司"）首次公开 发行股票并在科创板上市的持续督导保荐机构，根据《中华人民共和国证券法》 《证券发行上市保荐业务管理办法》《上海证券交易所上市公司自律监管指引第 规定，对峰岹科技 2024 年年度利润分配所涉及的差异化分红进行了核查，核查 情况及核查意见如下： 一、本次申请特殊除权除息处理的原因 五次会议，审议通过了《关于使用超募资金以集中竞价交易方式回购公司股份方 案的议案》，同意公司以超募资金通过集中竞价交易方式回购公司发行的人民币 普通股（A 股）。回购的股份将在未来适宜时机全部用于员工持股计划或股权激 励计划。回购的价格不超过人民币 178 元/股（含），回购的资金总额不低于人民 币 2,000 万元（含），不超过人民币 3,000 万元（含）。回购期限自董事会审议通 过回购股份方案之日起 12 个月内。 公司于 2024 年 1 月 31 日至 2024 年 9 月 10 日间累计回购公司股份 ...

Core Viewpoint - The accumulation of OCI (Other Comprehensive Income) floating profits in banks has been largely consumed, primarily due to passive consumption from a weak bond market rather than active selling by banks. The pressure on net interest margins is mainly observed in large banks, and with the alleviation of the "lack of liabilities" issue in Q2, a clearer bottom for net interest margins is expected [1][15]. Group 1: OCI Floating Profit Consumption - Most banks have consumed over half of their OCI floating profit accumulation, with some banks even turning to floating losses. Among the six major banks, one has consumed about half of its floating profit accumulation, while others have consumed around one-third. In total, 25 out of 33 listed banks have consumed more than half of their OCI floating profits, with 7 turning to floating losses [2][5]. - The low performance of bond market investment returns has significantly dragged down the revenue performance of listed banks. In Q1, non-interest income reduced the revenue growth of joint-stock banks and city commercial banks by 3.81 percentage points and 6.42 percentage points, respectively, while the contribution to rural commercial banks dropped from 7.30 percentage points to 4.52 percentage points [2][5]. Group 2: Net Interest Margin Pressure - The pressure on net interest margins and the resistance to recovery are primarily seen in large banks, which have passively shifted to interbank certificates of deposit and interbank fixed deposits due to a "lack of liabilities" in Q1. The average net interest margin for large banks narrowed by 0.10 percentage points to a low of 1.39% in Q1 [15]. - The alleviation of the "lack of liabilities" pressure and the stabilization of interbank deposit scale and prices are expected to lead to a significant easing of net interest margin narrowing pressure for large banks in Q2, reflecting the effectiveness of previous measures to reduce funding costs [15]. Group 3: Retail Loan Risks - Risks in retail loans remain, with no consistent trend of alleviation observed. Banks with a higher proportion of retail loans face greater difficulty in reducing non-performing loan rates compared to their peers, and the speed of provision consumption is faster [9]. - An analysis of three state-owned banks with retail loan ratios exceeding 50% shows a divergence in the direction and magnitude of changes in provision coverage ratios, the proportion of loans under scrutiny, and non-performing loan rates [9].

| > 龙虎榜 | | | | | | Q、输入问句,你想知道的都在这里 | | 开始搜索 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-05-16 | 2025-05-14 | 2025-05-12 | 2025-05-09 | | 2025-05-08 | | | 历史龙虎榜信息>> | | 上榜原因:日涨幅偏离值达7%的证券 | | | | | | | | 更多个股解读> | | 营业部名称 | | | | 买入金额(元) | 占总成交比例 | 卖出金额(元) | 占总成交比例 | 净额(元) | | 国泰海通证券股份有限公司三亚迎宾路证券营业部 | | | | 3.57亿 | 9.90% | 4.74万 | 0.00% | 3.57亿 | | 机构专用 | | | | 9507.16万 | 2.64% | 2645.67万 | 0.73% | 6861.49万 | | 国盛证券有限责任公司宁波天童南路证券营业部 | | | | 8070.80万 | 2.24% | 158.39万 | 0.04% | 7912.41万 ...

Core Viewpoint - The company, Jinlang Technology, is responding to an inquiry regarding its application for issuing convertible bonds, highlighting its revenue sources, financial performance, and market conditions in the photovoltaic industry [1][10]. Financial Performance - The company's operating revenue from 2021 to the first nine months of 2024 was 3.31 billion, 5.89 billion, 6.10 billion, and 5.16 billion CNY respectively, with inverter product sales and distributed photovoltaic power generation being the main revenue sources [1][12]. - The sales revenue from grid-connected inverters was 1.02 billion, 3.79 billion, 4.06 billion, and 4.00 billion CNY, while the sales revenue from energy storage inverters was 175.78 million, 1.07 billion, 438.70 million, and 383.00 million CNY [1][12]. - The company's gross profit margin for the reporting periods was 28.71%, 33.52%, 32.38%, and 33.67%, with the gross margin for photovoltaic inverter business declining [2][4]. Market Environment - The global photovoltaic market is experiencing growth, driven by the transition to renewable energy and the decreasing costs of photovoltaic technology, leading to increased demand for inverters [11][14]. - The company is focusing on expanding its presence in emerging markets such as India and Pakistan, which are expected to drive future growth in inverter demand [14][12]. Business Structure - The company has established two core business segments: photovoltaic inverters and distributed photovoltaic power generation, with the inverter business focusing on string inverters [12][13]. - The revenue contribution from distributed photovoltaic power generation has been increasing, with its gross profit contribution exceeding 50% in recent periods [14][12]. Customer Dynamics - The company has seen significant changes in its top five customers during the reporting period, with new customers such as Luminous Power Technologies and AE SOLAR ALTERNATIVE ENERGY emerging [3][12]. - Accounts receivable have increased, with the balance at the end of each period being 482.37 million, 1.05 billion, 936.07 million, and 1.51 billion CNY, indicating a trend of decreasing proportion of receivables aged within one year [3][4]. Financial Health - The company's total liabilities increased from 407.07 million CNY at the end of 2021 to 1.36 billion CNY by September 2024, with a debt ratio that fluctuated but remained below industry averages [4][10]. - The cash balance at the end of each period was 747.33 million, 1.58 billion, 1.08 billion, and 1.11 billion CNY, indicating a need for careful liquidity management [4][10].

国泰海通证券股份有限公司、德邦证券股份有限公司 关于海南矿业股份有限公司 差异化权益分派事项的核查意见 国泰海通证券股份有限公司（以下简称"联合保荐人"或"国泰海通"）、德邦 证券股份有限公司（以下简称"联合保荐人"或"德邦证券"）作为海南矿业股份有 限公司（以下简称"海南矿业"或"公司"）持续督导工作的保荐人，根据《证券发 行上市保荐业务管理办法（2023年修订）》《上海证券交易所上市公司自律监 管指引第7号——回购股份（2023年12月修订）》等有关规定，对海南矿业差 异化权益分派特殊除权除息事项进行了审慎核查，发表核查情况说明如下： 一、本次差异化权益分派的原因 于以集中竞价交易方式回购股份方案的议案》，回购的股份将在未来适宜时间 用于股权激励或员工持股计划，回购价格不超过人民币9.71元/股（含），回购 资金总额不低于人民1.5亿元（含），不超过人民币3亿元（含），回购期限自 董事会审议通过回购股份方案之日起12个月内。 公司于2023年11月20日实施了首次回购。2024年3月4日，公司完成该次回 购方案，合计回购公司股份48,271,626股，占公司当时总股本的比例为2.37%。 截至2025年4 ...